# a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）

> **NCT07128797** · PHASE1 · RECRUITING · sponsor: **Tasly Biopharmaceuticals Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- NAFLD (Non-alcoholic Fatty Liver Disease)
- NASH (Nonalcoholic Steatohepatitis)

## Interventions

- **DRUG:** B1344
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07128797
- **Lead sponsor:** Tasly Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-24
- **Primary completion:** 2026-06
- **Final completion:** 2026-07
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07128797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07128797, "a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07128797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*